Colorado will be part of a 37-state, $90 million settlement with GlaxoSmithKline to resolve allegations that the drug manufacturer unlawfully promoted Avandia, a diabetes medication.
Under the settlement, announced by Attorney General John Suthers, the state will receive $1.9 million in funds because the pharmaceutical company did not disclose all the medication’s negative side effects.
The attorney general says GlaxoSmithKline engaged in unfair and deceptive practices my misrepresenting Avandia’s cardiovascular risks and safety profile.
“GlaxoSmithKline must be straight with consumers about the known risks of its drug Avandia,” said Suthers. “After announcing a historic healthcare settlement in July,GSK is again paying a price for its bad behavior.. This settlement should serve as a warning to all drug manufacturers.”
As part of the settlement, GlaxoSmithKline agreed to reform how it markets and promotes diabetes drugs. Under the Consent Judgment, GSK may not make false claims, make safety claims not supported by evidence, and it cannot present favorable information as valid when it isn’t. The company can’t promote investigation drugs or misuse statistics to bolster false claims.